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Polo-like kinase 1 (Plk1), an essential regulator of cell division, is currently 48 
undergoing clinical evaluation as a target for cancer therapy. We report an 49 
unexpected function of Plk1 in sustaining cardiovascular homeostasis. Plk1 50 
haploinsufficiency in mice did not induce obvious cell proliferation defects but 51 
resulted in arterial structural alterations, frequently leading to aortic rupture and 52 
death. Specific ablation of Plk1 in (VSMC) led to reduced arterial elasticity, 53 
hypotension, and an impaired arterial response to angiotensin II in vivo. 54 
Mechanistically, we found that Plk1 regulates angiotensin II-dependent activation 55 
of RhoA and actomyosin dynamics in VSMCs in a mitosis-independent manner. 56 
This regulation depends on Plk1 kinase activity, and administration of small 57 
molecule Plk1 inhibitors to angiotensin II-treated mice led to reduced arterial 58 
fitness and an elevated risk of aneurysms and aortic rupture. Thus, a partial 59 
reduction of Plk1 activity that does not block cell division can nevertheless impair 60 
aortic homeostasis, a finding with potentially important implications for current 61 








Current therapeutic efforts to treat tumors include strategies aimed at inhibiting the 68 
activity of cell cycle enzymes such as mitotic kinases. Polo-like kinase 1 (Plk1) is an 69 
essential protein kinase, originally discovered in Drosophila1,2, that plays multiple roles 70 
in centrosome maturation and separation, DNA replication, chromosome segregation, 71 
and cytokinesis3-5. Chemical inhibition or RNA interference targeting Plk1 results in 72 
prometaphase arrest due to monopolar spindles or misaligned chromosomes, as well as 73 
specific defects during cytokinesis4,6,7. However, the functional roles of this kinase have 74 
been mostly characterized in cellular systems and its physiological relevance in 75 
mammals is largely unknown.  76 
Plk1 is overexpressed in human tumors and its expression level has prognostic 77 
value, leading to the development of a number of small-molecule inhibitors that are 78 
currently in clinical trials for cancer therapy4,8,9. One of these inhibitors, volasertib 79 
(BI6727), recently received a Breakthrough Therapy designation by the FDA due to its 80 
significant therapeutic effect in acute myeloid leukemia (AML) patients10,11. 81 
 We show here that both Plk1 mutant mice and mice treated with Plk1 inhibitors 82 
display an unexpected defect in arterial structure, leading to aortic rupture and lethality. 83 
We demonstrate that Plk1 is specifically required in postmitotic vascular smooth muscle 84 
cells (VSMCs) for RhoA activation and vasoconstriction. The requirement of Plk1 for 85 
normal arterial structure has implications for the clinical use of Plk1 inhibitors.  86 
RESULTS 87 
Cardiovascular defects in Plk1(+/–) mice 88 
Plk1 is an essential gene in the mouse and homozygous genetic ablation of Plk1 in the 89 
germline [Plk1(–/–)] results in early embryonic lethality12,13. We recently generated a 90 
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conditional knockout allele [Plk1(lox)] in which exon 2 of the Plk1 gene is flanked by 91 
loxP sites13,14. To study the physiological consequences of Plk1 inactivation in adult 92 
mice, we intercrossed Plk1(lox/lox) conditional knockout mice with knockin mice 93 
expressing a ubiquitously-expressed, tamoxifen-inducible Cre recombinase (a Cre-94 
estrogen receptor (ERT) fusion protein15). We injected young (3-month old) 95 
Plk1(lox/lox);Cre-ERT and control mice with tamoxifen intraperitoneally (i.p.) to 96 
activate Cre, leading to excision of Plk1 exons and thereby generating the Plk1(Δ) 97 
allele. All treated Plk1(Δ/Δ) mice died within 10 days, whereas control mice were alive 98 
for the duration of the experiment (Fig. 1a). Plk1-deficient mice rapidly lost weight 99 
(Fig. 1b) and had an altered architecture of the intestinal mucosa (Fig. 1c), suggesting 100 
that defective nutrient absorption was the primary cause of death in these mice. The 101 
intestinal mucosa showed a high number of cells with aberrant mitosis, as detected by 102 
phospho(S10)-histone H3 staining (Fig. 1c,d). Lack of Plk1 also resulted in dramatic 103 
loss of cellularity in the bone marrow and a significant alteration in blood cell 104 
populations (Supplementary Fig. 1a,b), consistent with an essential role of Plk1 in 105 
rapidly proliferating cells.  106 
Due to the rapid lethality after complete Plk1 ablation, we next focused our 107 
attention on Plk1(+/–) heterozygous mice. Although these mice were viable and fertile 108 
with no obvious defects in proliferative tissues (Supplementary Fig. 1c-e), the viability 109 
of these mice was significantly compromised, as ~50% of Plk1(+/–) mice died by 1.5-110 
years of age (Fig. 1e). Unexpectedly, in about half of these cases, Plk1(+/–)  mice died 111 
as a consequence of massive hemorrhaging in the thoracic or abdominal cavities. 112 
Histopathological analysis identified aortic dissection as the main cause of death (Fig. 113 
1f and Supplementary Table 1). Aortic sections from Plk1(+/–) mice showed features of 114 
media degeneration, including elastic fiber fragmentation and disorganization, as well as 115 
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accumulation of mucopolysaccharides (Fig. 1f,g and Supplementary Fig. 2a). Despite 116 
no significant differences in blood pressure when compared to wild-type Plk1(+/+) 117 
littermates (Supplementary Fig. 2b), Plk1(+/–) mice showed aortic wall thickening 118 
(Supplementary Fig. 2c). Fine-structure analysis by transmission electronic microscopy 119 
confirmed an abnormal organization of elastic fibers and vacuolization of smooth 120 
muscle cells in the aorta (Supplementary Fig. 2a). Notably both the ascending and 121 
descending thoracic and abdominal aortas of Plk1(+/–) mice showed a significant 122 
dilation of the internal diameter (Fig. 1h and Supplementary Fig. 2d). Finally, total 123 
RNA was extracted from the aortas of 3-5-month-old Plk1(+/–) and Plk1(+/+) mice and 124 
we performed microarray analysis to compare gene expression. Plk1(+/–) aortas were 125 
characterized by a significant downregulation of genes involved in muscle and 126 
cardiovascular function, energy production, actin cytoskeleton dynamics, and the Rho-127 
mediated signaling pathway (Supplementary Fig. 2e and Supplementary Tables 2-3). 128 
Plk1 activity is required for vascular contractility 129 
Plk1 is expressed mostly in proliferating tissues16 (Supplementary Fig. 3a,b), raising 130 
questions about the importance of this protein in vascular function in adult mammals. 131 
An initial analysis of data available in public databases indicated that Plk1 is expressed 132 
in the aorta, and that Plk1 mRNA is more abundant in the aorta of hypertensive than 133 
normo- or hypotensive mice (Supplementary Fig. 3c). We therefore examined Plk1 134 
expression in adult (3 month old) mice in a model of angiotensin II (AngII)-induced 135 
hypertension. We did not detect Plk1 protein in aortas from control, untreated mice by 136 
either immunoblotting or immunohistochemistry (Supplementary Fig. 3b,d). However, 137 
a significant but transient increase in Plk1 mRNA and protein levels was observed 3-6 138 
days after treatment with AngII (Supplementary Fig. 3d-f). This treatment did not result 139 
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in increased levels of the proliferation marker Ki67 or mitotic phosphorylation of 140 
histone H3 (Supplementary Fig. 3g), indicating that transcriptional induction of Plk1 141 
was not a consequence of increased cell cycle entry.  142 
To test the physiological requirement of Plk1 in VSMCs and in arterial function, 143 
we specifically ablated Plk1 in VSMCs by intercrossing Plk1(lox/lox) mice with SM22-144 
Cre transgenic mice expressing tamoxifen-inducible Cre recombinase under the control 145 
of the mouse Tagln (transgelin; smooth muscle protein 22-alpha) promoter17. After 146 
tamoxifen treatment, these mice (referred to as Plk1(Δ/Δ)SM mice) showed efficient 147 
excision of Plk1 in the aorta but not in other tissues such as heart (Fig. 2a), and this 148 
gene excision in the aorta correlated with significantly diminished aortic Plk1 transcript 149 
levels (Fig. 2b). After 4 months on a tamoxifen-supplemented diet, 7-8-month-old 150 
Plk1(Δ/Δ)SM mice had dilated ascending aortas (Fig. 2c) and were hypotensive (Fig. 2d) 151 
when compared to Plk1(lox/lox) mice fed with tamoxifen in the absence of the SM22-152 
Cre allele (referred to as Plk1(lox/lox) mice). Plk1(Δ/Δ)SM mice also displayed reduced 153 
aortic elasticity, as assessed using isolated aortic rings in a myograph (Fig. 2e). 154 
Similarly, the contractile response of aortic rings from Plk1(Δ/Δ)SM mice to AngII or 155 
phenylephrine was defective (Fig. 2f), and mesenteric arteries from these mice showed a 156 
significantly reduced response to phenylephrine, but not to AngII, (Supplementary 157 
Figure 4a). 158 
We next tested the impact of VSMC-specific Plk1 ablation on AngII-induced 159 
hypertension. AngII treatment induced Plk1 mRNA expression in control but not 160 
Plk1(Δ/Δ)SM mice (Supplementary Fig. 4b), and induced a strong increase in blood 161 
pressure in control mice, whereas this effect was much more limited in Plk1(Δ/Δ)SM 162 
mice (Fig. 2g). AngII-induced cardiac hypertrophy was also less severe in Plk1(Δ/Δ)SM 163 
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than in control mice (Fig. 2h); this effect correlated with smaller increases in the heart 164 
wall thickness (Fig. 2i) and cardiomyocyte cross-sectional area (Fig. 2j). Interestingly, 165 
Plk1(Δ/Δ)SM mice had a larger internal aortic diameter than control mice with or without 166 
AngII treatment (Supplementary Fig. 4c). More importantly, Plk1 ablation resulted in a 167 
significant increase in the number of elastic fiber breaks as compared to control mice 168 
(Fig. 2k), as we previously observed in Plk1(+/–) mice. Together, these data suggest 169 
that Plk1 deficiency in VSMCs results in a cell autonomous defect characterized by 170 
structural defects in the tunica media of the aorta, reduced elasticity and a defective 171 
response to AngII. 172 
Plk1-deficient VSMCs have an impaired RhoA pathway 173 
To study the mechanistic relevance of Plk1 in vascular cells, we next generated VSMC 174 
cultures in which the Plk1 gene could be conditionally ablated. To avoid the possibility 175 
that ablation of Plk1 would cause mitotic defects, VSMCs isolated from Plk1(lox/lox) 176 
mice were arrested in G0 by culture in low serum (0.1% FBS) and confluency, and then 177 
transduced by adenovirus expressing Cre recombinase, thereby generating a Plk1 null 178 
allele [Plk1(Δ)] in quiescent cells (Fig. 3a). Two days later, cells were analyzed either in 179 
G0 or in early G1, at time points from 2–10 h after the addition of lysophosphatidic acid 180 
(LPA) or Angiotensin II (AngII) to rule out mitotic defects after Plk1 ablation 181 
(Supplementary Fig. 5a,b). Six hours after induction with LPA, control cells showed an 182 
elongated or polygonal morphology with well-defined actin stress fibers, whereas 183 
Plk1(Δ/Δ) cells had a more rounded shape with fewer actin fibers (Fig. 3b,c and 184 
Supplementary Fig. 5c). Treatment of serum-starved cells in G0 with AngII or LPA 185 
induces the formation of stress fibers through activation of RhoA and subsequent 186 
phosphorylation of myosin light-chain (MLC)18. Lack of Plk1 resulted in impaired 187 
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phosphorylation of MLC and MYPT1 (Fig. 3d and Supplementary Fig. 5c) and 188 
inefficient activation of RhoA (Fig. 3e). We observed similar defects in interphase wild-189 
type VSMCs when Plk1 was chemically inhibited using either of two different small-190 
molecule kinase inhibitors, BI2536 and GW843682X (Fig. 3f,g and Supplementary Fig. 191 
5b-d), indicating that these alterations are not an artefactual consequence of genetic 192 
modification of the Plk1 locus, but rather due to deficient Plk1 activity. The Plk1 193 
inhibitor BI2536 was also efficient in preventing AngII- or phenylephrine-induced 194 
contraction in aortic rings (Figure 3h) and in mesenteric arteries (Supplementary Fig. 195 
5e). 196 
 To determine the relevance of RhoA signaling downstream of Plk1, we repeated 197 
these assays using Y27632, a specific inhibitor of RhoA-associated coil kinase (ROCK), 198 
or using VSMCs expressing a constitutively-active form of RhoA (the Q63L mutant). 199 
ROCK inhibition resulted in effects on stress fiber formation and cell morphology (Fig. 200 
3i,j), as well as on MLC phosphorylation (Supplementary Fig. 5b), that were similar to 201 
those observed in Plk1-null cells. Notably, expression of RhoA Q63L rescued the 202 
response of Plk1-deficient cells to LPA (Fig. 3i,j) and to AngII (Supplementary Fig. 5f), 203 
suggesting that the morphological and functional alterations induced by Plk1 inhibition 204 
are largely due to defective activation of the RhoA GTPase.  205 
Plk1 modulates RhoA activity in an Ect2-dependent manner 206 
We next investigated the molecular mechanism linking Plk1 and RhoA. RhoA is a small 207 
GTPase activated by guanine exchange factor (GEF)-mediated GDP/GTP exchange. 208 
Several RhoGEFs have been implicated in actin dynamics in VSMCs, including 209 
p115GEF (also known as ArhGEF1; ref. 19), LARG (ArhGEF12; ref. 20), p63RhoGEF 210 
(ref. 21) and PDZ-RhoGEF (ref. 22). On the other hand, several RhoGEFs, such as 211 
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epithelial cell transforming sequence 2 (Ect2) and MyoGEF, have been proposed to 212 
regulate RhoA activity during cytokinesis, in which RhoA activation is locally required 213 
for the positioning and assembly of the cytokinetic apparatus and acto-myosin 214 
contraction at the mitotic furrow (reviewed in ref. 6).  215 
We first tested the expression of each of these GEFs in the context of 216 
hypertension. Inspection of data in public repositories showed that, similarly to Plk1, 217 
Arhgef1 (encoding p115GEF) and Ect2 transcripts were more abundant in aortas from 218 
hypertensive mice as compared to normo- or hypotensive mice; however, there was no 219 
significant increase in the transcripts encoding MyoGEF, LARG, PDZ-RhoGEF or p63-220 
RhoGEF (Supplementary Fig. 6). We verified these data using RNA from aortas of 221 
AngII-treated mice. AngII treatment led to an increase in Ect2, Plekhg6 (encoding 222 
MyoGEF) and Arhgef1 mRNA levels, as assessed 6 days after treatment (Fig. 4a), 223 
whereas Arhgef12 (encoding LARG) mRNA levels were not affected, in agreement with 224 
published data suggesting that LARG activity is responsive mainly to salt-induced 225 
hypertension20. To test the involvement of these GEFs in the regulation of VSMC 226 
cytoskeletal dynamics, we tested the effect of RNA interference-mediated GEF 227 
depletion on the cell roundness factor. When either Ect2 or p115GEF were depleted, 228 
VSMCs did not polarize properly in the presence of LPA (Fig. 4b, c), whereas LARG or 229 
MyoGEF depletion had no effects. Similar studies using AngII showed that Ect2 is a 230 
critical factor for both AngII-induced morphological changes (Fig. 4d) and MLC 231 
phosphorylation (Fig. 4e). Thus, activation of RhoA by AngII may be mediated not only 232 
by p115GEF but also by Ect2, indicating that Ect2 may have cell-cycle-independent 233 
functions in controlling RhoA activity. 234 
The recruitment of Ect2 to the cleavage furrow during cytokinesis depends on 235 
Plk1-mediated phosphorylation of the Rho GTPase activating protein (GAP) RacGAP1 236 
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(also known as MgcRacGAP or HsCyk4); RacGAP1 therefore counterintuitively 237 
functions as a RhoA activator via Ect2 recruitment23-27. Racgap1 mRNA expression was 238 
significantly induced in aortas from AngII-treated mice (Fig. 4a), and RacGAP1 239 
depletion in VSMCs led to similar defects in cell roundness (Fig. 4b,d) and 240 
phosphorylation of MLC (Fig. 4e) to those observed after Plk1 inactivation. 241 
During cytokinesis, Plk1 is known to phosphorylate several sites in the N-242 
terminal domain of RacGAP1, thereby generating a docking site for the tandem BRCT 243 
repeats of Ect2 (refs. 25,26). We found that one of these N-terminal domain residues of 244 
RacGAP1, Ser170, was phosphorylated 10-30 min after treatment of quiescent VSMCs 245 
cells with LPA or AngII (Fig. 4f,g), concomitantly with phosphorylation of MLC (used 246 
as a read-out of RhoA pathway activation). Notably, phosphorylation of both RacGAP1 247 
and MLC were impaired by Plk1 inhibition with BI2536. Moreover, inhibition of Plk1 248 
with BI2536 prevented the binding of Ect2 to RhoA in quiescent VSMCs 20 min after 249 
stimulation with LPA (Fig. 4h). Plk1 activity was also required for the binding of wild-250 
type RacGAP1 to RhoA, whereas a RacGAP1 mutant with four phospho-mimetic (Ser-251 
to-Asp) mutations at positions Ser149, Ser159, Ser164 and Ser170 (4D mutant; ref. 26) 252 
bound to RhoA independently of Plk1 activity (Fig. 4h).  253 
Activation of RhoA by Ect2 depends on both Plk1 and atypical PKC 254 
In interphase cells, Plk1 is localized to both the cytoplasm and nucleus, without any 255 
obvious concentration in cellular membranes6. RacGAP1 and Ect2 are mostly nuclear, 256 
although RacGAP1 can also localize to microtubule-dense regions in the cytoplasm28, 257 
as well as to cell-cell contact regions in the plasma membrane29. We therefore tested 258 
whether these proteins are re-distributed upon stimulation of the RhoA pathway in 259 
VSMCs. Upon treatment with AngII, endogenous Plk1 was clearly enriched in cell 260 
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protrusions that were also enriched for phosphorylated MLC (Fig. 5a). A similar re-261 
distribution of Plk1 was observed in LPA-stimulated VSMCs expressing a GFP-Plk1 262 
fusion protein (Supplementary Figure 7a). We could not study effects on the 263 
localization of endogenous Ect2 protein, because available antibodies are of insufficient 264 
quality. However, in VSMCs expressing a GFP-Ect2 fusion protein, a pool of GFP-265 
Ect2, which was mostly nuclear-localized prior to stimulation, shuttled to the cytoplasm 266 
at ~10 min after LPA treatment (Fig. 5b and Supplementary Fig. 7a). This cytoplasmic 267 
pool of Ect2 localized preferentially to cell protrusions and remained in these 268 
protrusions for at least the following 2 h. We did not observe any substantial changes in 269 
the subcellular localization of a GFP-RacGAP1 fusion protein in response to LPA (data 270 
not shown). These results suggest that both Plk1 and Ect2 are dynamically redistributed 271 
in the cell upon stimulation of the RhoA pathway.  272 
Since Plk1 has been proposed to phosphorylate Ect2 during cytokinesis30, we 273 
analyzed effects of LPA on the phosphorylation of specific Ect2 residues by mass 274 
spectrometry. In HEK293 cells, we identified two Ect2 residues (Thr327 and Ser335) 275 
specifically phosphorylated after treatment with LPA. It is worth mentioning that we did 276 
not find phosphorylation at either of the sites reported to be phosphorylated by Cdk1 277 
(Thr341 and Thr412), which are required for Ect2 function during cytokinesis31. 278 
Notably, Thr327, but not Ser335, is a putative PDB-binding site, as it is adjacent to a 279 
proline residue (Supplementary Fig. 7b,c), and previous reports have demonstrated that 280 
the atypical protein kinase C (aPKC) PKCι can phosphorylate Ect2 at this threonine 281 
residue in cancer cells and thereby regulate its nuclear export32. We therefore 282 
hypothesized that binding of Ect2 to Plk1 and RhoA could be modulated by aPKC–283 
dependent phosphorylation. Indeed, we found that Ect2 efficiently bound to Plk1 20 284 
minutes after LPA induction, and that this binding was substantially impaired by 285 
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treatment with the PKC inhibitor Go6983 (Fig. 5c). This inhibitor also prevented 286 
elongation of VSMCs, an effect similar to that of the ROCK inhibitor Y27632 or Plk1 287 
ablation (Fig. 5d); however, Go6983 had no significant effect in Plk1-deficient cells 288 
(Supplementary Fig. 7d), suggesting a critical role of aPKC in the binding of Ect2 to 289 
RhoA and subsequent changes in cell morphology. We tested the requirement for Plk1, 290 
ROCK and aPKC activity in arterial contraction in an independent manner using 291 
specific Plk1, ROCK or aPKC inhibitors (BI2536, Y27632 and GO6983, respectively) 292 
in aortic rings isolated from wild-type mice. Phenylephrine-induced contraction of these 293 
rings was significantly reduced by each of these inhibitors, with the ROCK inhibitor 294 
showing the strongest effect (Supplementary Fig. 7e). 295 
We next tested the importance of Ect2 Thr327 phosphorylation by generating a 296 
phosphorylation-resistant mutant, in which Thr327 was mutated to Ala. RhoA-17A-297 
coated-beads efficiently pulled down wild type GFP-Ect2 but not mutant Ect2 T327A, 298 
from lysates of LPA-treated HEK293 cells (Fig. 5e). Similarly, the Ect2-T327A mutant 299 
displayed lower affinity for the Plk1 Polo-box domain (Plk1-PBD) compared to wild 300 
type Ect2 (Fig. 5f), suggesting that Plk1 can recognize and bind Ect2 when it is 301 
phospho-primed at the Thr327 residue. Moreover, whereas wild-type Ect2 but not the 302 
Ect2-T327A mutant could efficiently rescue the defect in cell elongation caused by Ect2 303 
deficiency (Fig. 5g). However, Ect2-T327A was able to rescue cell division defects 304 
caused by Ect2 deficiency (Supplementary Fig. 7f), suggesting that phosphorylation of 305 
Ect2 at T327 is dispensable during mitosis or cytokinesis but participates in cytoskeletal 306 
re-arrangements during interphase. 307 
We also analyzed whether Plk1-mediated phosphorylation of Ect2 could 308 
contribute to the activation of RhoA. We generated an Ect2 mutant, designated the 14A 309 
mutant, containing alanine substitutions at all 14 D/E/N-X-S/T-ϕ sites (putative sites of 310 
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Plk1-mediated phosphorylation, where X represents any amino acid residue and ϕ 311 
denotes a hydrophobic residue) of Ect2. This mutant protein was phosphorylated by 312 
recombinant Plk1 in vitro to a much lower extent than was wild-type Ect2 313 
(Supplementary Fig. 7g,h). However, unlike the T327A mutant, the 14A mutant 314 
displayed normal binding to RhoA (Fig. 5e). In addition, we did not detect 315 
phosphorylation of any of these 14 sites after stimulation of HEK293 expressing GFP-316 
Ect2 with LPA (data not shown). Thus, although we cannot rule out the possibility that 317 
Ect2 is phosphorylated by Plk1, we did not find evidence for Ect2 regulation by direct 318 
phosphorylation by Plk1. Taken together, these data suggest that Ect2 phosphorylation 319 
at Thr327 by aPKC mediates the interaction of Plk1 and Ect2, thereby promoting RhoA 320 
activity and actin cytoskeleton dynamics in interphase VSMCs. 321 
 322 
Plk1 inhibitors induce aortic dilation and defective vascular function 323 
In view of the effects Plk1 inhibition on VSMC function in vitro, we next tested 324 
whether Plk1 inhibition would affect vascular homeostasis in adult mice in vivo. We 325 
treated wild-type mice with 15 mg/kg volasertib, the Plk1 inhibitor that has advanced 326 
furthest in the clinic, for 1 month, and then with AngII plus volasertib for an additional 327 
4 weeks (Fig. 6a). At this low dose, volasertib treatment did not induce weight loss or 328 
reduce peripheral blood cell counts, suggesting that it did not cause major defects in cell 329 
proliferation (Supplementary 8a,b). However, consistent with the phenotype of Plk1-330 
deficient aortas, aortic rings isolated from mice treated with volasertib for eight weeks 331 
treatment had defective elasticity (Fig. 6b). Although volasertib treatment induced an 332 
initial and transient small increase in blood pressure (Supplementary Fig. 8c), the 333 
hypertension that is typically induced by AngII treatment was significantly impaired by 334 
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Plk1 inhibition (Fig. 6c), consistent with the effect of VSMC-specific Plk1 deficiency in 335 
Plk1(Δ/Δ)SM mice. Treatment with volasertib (Fig. 6d) or GW843682X (Supplementary 336 
Fig. 8d-f) reduced AngII-induced cardiac hypertrophy, as was also observed in the 337 
genetic model. 338 
 Ultrasound analysis of wild-type mice treated with volasertib for  1 month 339 
showed significant dilation of the abdominal aorta in the suprarenal region 340 
(Supplementary Fig. 8g). This effect was more pronounced after volasertib treatment for 341 
2 months, especially in the ascending aorta and descending aorta close to the diaphragm 342 
(Fig. 6e). Moreover, treatment with either volasertib or AngII significantly increased 343 
elastic fiber fragmentation when compared to untreated mice, and combined treatment 344 
with volasertib and AngII had greater effects than treatment with either alone (Fig. 6f). 345 
Strikingly, combined treatment with AngII and volasertib induced aneurysms (4/8 mice) 346 
and aortic dissections (3/8 mice; Fig. 6g), whereas these were never observed after 347 
treatment with either of these agents alone (0/6 AngII- and 0/5 volasertib-treated mice). 348 
Together, these results suggest that Plk1 participates in VSMC function in vivo in a 349 
manner dependent on its kinase activity, and that sustained treatment with Plk1 350 
inhibitors may result in altered AngII responses and pronounced vascular defects. 351 
 352 
DISCUSSION 353 
Plk1 is essential for mitosis in all eukaryotes where its function has been tested5-7. 354 
Whereas whole-body ablation of Plk1 is highly toxic in adult mice, Plk1(+/–) mice 355 
develop normally and cells derived from these heterozygous mutants do not display 356 
obvious defects in cell proliferation13. However, we found that Plk1 haploinsufficiency 357 
results in a syndrome of cardiovascular defects and premature lethality, due primarily to 358 
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aortic rupture. The structure of the aorta is disrupted in Plk1(+/–) mice, and 359 
transcriptional profiling suggests that these defects may arise, at least in part, from 360 
abnormalities in the RhoA pathway and in the actomyosin cytoskeleton. Although Plk1 361 
is known to be highly expressed in proliferative tissues16, we found that Plk1 is also 362 
expressed at low levels in the aorta and that AngII treatment of mice led to 363 
transcriptional induction of Plk1 and other members of the RhoA pathway. Specific 364 
ablation of Plk1 in VSMCs resulted in stiffening of the aorta and a defective response to 365 
AngII in vivo, as well as defective RhoA-dependent actomyosin cytoskeleton dynamics 366 
in VSMCs in vitro. Expression of constitutively activated RhoA rescued the defective 367 
actomyosin dynamics, suggesting that RhoA is a major target of Plk1 in these cells. 368 
The control of myosin contractility by Polo-like kinases is conserved through 369 
evolution6,33-35. During cytokinesis, Plk1 is required to generate an area in which RhoA 370 
is active and where ingression of the cleavage furrow originates. Plk1 modulates RhoA 371 
function during cytokinesis through direct phosphorylation of the RhoA exchange factor 372 
Ect2, although the precise residues that are phosphorylated remain elusive26,30. Recent 373 
data have established a mechanism in which Plk1 phosphorylates the GTPase-activating 374 
protein RacGAP1, which subsequently recruits Ect2 to the area of the cleavage furrow, 375 
thereby promoting RhoA activation in the middle of the cell23-26. 376 
Despite this previously established cell-cycle-dependent connection between 377 
Plk1 and RhoA, our finding that Plk1 is haploinsufficient for vascular homeostasis was 378 
unexpected. Different GEFs have been suggested to play a role in the activation of 379 
RhoA in smooth muscle cells, including LARG 20, p115RhoGEF 19, p190RhoGEF and 380 
GEF-H1 36. In particular, in mice deficient for p115GEF, RhoA is not activated upon 381 
AngII treatment19, whereas in mice deficient for LARG, RhoA is not activated in a 382 
model of salt-induced hypertension20. Although the role of the GEF Ect2 in RhoA 383 
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activation in these settings has not been established, Ect2 expression is upregulated in 384 
mice with AngII-induced hypertension37. We observed that the mRNA levels of Plk1 385 
and Racgap1, in addition to those of Ect2, are elevated in mice with AngII-induced 386 
hypertension. Despite the fact that Ect2 is mostly localized to the nucleus, Ect2 has been 387 
implicated in cell polarity38, is able to activate Rho signaling at the zonula adherens in 388 
epithelial cells29, and can shuttle from the nucleus to the cytoplasm after 389 
phosphorylation by either atypical-PKC (aPKC)39 or Cdk140,41. Moreover, PKC 390 
enzymes have been proposed to mediate RhoA-dependent alteration of vascular 391 
physiology, although the underlying mechanisms are not fully understood42,43. Our data 392 
suggest that aPKC may contribute to the regulation of actomyosin dynamics in VSMCs 393 
through the phosphorylation and nuclear export of Ect2. The residue of Ect2 394 
phosphorylated by aPKC, Thr327, is located in the so-called “hinge” domain of Ect2, 395 
very close to the two central NLS sequences and to sites phosphorylated by Cdk1. 396 
During mitosis, phosphorylation of Ect2 by Cdk1 at T412 regulates the binding of Ect2 397 
to Plk1, such that the Ect2 T412A mutant does not exhibit a strong association with 398 
Plk130. The observation that the Ect2 T327A mutant cannot be exported from the 399 
nucleus32 suggests that aPKC-dependent phosphorylation at Thr327 determines its 400 
nuclear export32 and binding to Plk1. Thus, both Cdks and aPKC may function to prime 401 
Ect2 for Plk1 binding, during mitosis and during interphase, respectively.  402 
The presence of elastic fiber breaks, aneurysms, and aortic dissections in 403 
Plk1(+/–) and Plk1(Δ/Δ)SM mice, as well as in wild-type mice treated with volasertib, 404 
indicate further functions of Plk1 in the maintenance of aortic structure. AngII treatment 405 
exacerbated the induction of elastic fiber breaks and aneurysms by Plk1 inhibition using 406 
volasertib. As we did not observe these phenotypes after specific ablation of Plk1 in 407 
VSMCs, we speculate that either Plk1 depletion in the Plk1(Δ/Δ)SM model is incomplete 408 
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or that volasertib has additional effects in other vascular cell types. The role of the 409 
Plk1/RhoA axis in the regulation of vascular contractility and homeostasis is consistent 410 
with findings that familial forms of thoracic aortic aneurysms and dissections (TAAD) 411 
are frequently caused by mutations that affect the structure and function of the 412 
contractile unit of medial smooth muscle cells44,45. These familial forms of TAAD are 413 
typically inherited in an autosomal dominant pattern with variable disease expression45. 414 
Similarly to Plk1 deficiency, loss-of-function mutations in the genes encoding smooth 415 
muscle myosin heavy chain (MYH11)46 or myosin light chain kinase (MLCK)47 result 416 
in impaired myosin contractility and aortic aneurysms and dissections, preferentially 417 
affecting the ascending aorta. Myh11 mutant mice have normal systemic blood pressure; 418 
however, VSMCs from these mice have impaired contractility48 and these mice have an 419 
above-normal incidence of aortic aneurysm and dissection in the presence of 420 
hypertension49. Elevated blood pressure and defective myosin contractility thus 421 
cooperate to generate these vascular defects. Targeted deletion of the mouse MLCK-422 
encoding gene, Mylk, in VSMCs results in hypotension accompanied by features of 423 
medial degeneration of the aorta47,50. Moreover, deletion of the counteracting 424 
phosphatase (myosin phosphatase target subunit 1) gene, Mypt1, results in increased 425 
intestinal smooth muscle contractility in response to specific stimuli51. Notably, Plk1 426 
forms a complex with MYPT152, suggesting that Plk1 may have RhoA-independent 427 
roles in myosin function. Plk1 can also regulate other cytoskeletal proteins related to 428 
cellular contraction, such as vimentin, and may thus have additional roles in cellular 429 
contraction, as shown in the airway smooth muscle53. Finally, whether Plk1 affects the 430 
structure or function of extracellular elastin fibers is an interesting possibility that 431 
deserves further investigation. 432 
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Plk1 inhibitors are currently in advanced clinical trials for cancer treatment9,54. 433 
The main adverse effects of these inhibitors that have been reported are hematological 434 
alterations such as anemia, neutropenia and thrombocytopenia, as well as 435 
gastrointestinal events, which are likely a consequence of the essential role of Plk1 in 436 
the cell cycle. A few treated individuals have been reported to experience 437 
thromboembolism or phlebitis55, hemorrhages56,57 and changes in blood pressure 438 
(Clinical trial NCT01121406 and Ref. 58), although to what extent these adverse events 439 
can be ameliorated by changes in dosing or treatment length is unclear at present. 440 
Nonetheless, our data suggest a note of caution in the use of Plk1 inhibitors, as they 441 
may have cardiovascular side effects, such as hypotension, hemorrhage and aneurysm, 442 
especially with extended treatment or with treatment of hypertensive patients. 443 
The observation that Plk1 haploinsufficiency results in deficient RhoA activation 444 
without obvious defects in the cell cycle suggests a stronger requirement for Plk1 445 
activity in the RhoA pathway than in sustaining cell proliferation. As RhoA is a critical 446 
mediator of major oncogenic or metastatic pathways59,60, the use of low doses of Plk1 447 
inhibitors could be considered as an attractive therapeutic strategy to limit the activation 448 
of these pathways in cancer cells. A better understanding of the physiological 449 
requirements for Plk1 in different tissues, either as an essential cell cycle kinase or as a 450 
RhoA regulator, will undoubtedly improve future therapeutic strategies aimed at 451 
inhibiting this kinase in human disease. 452 
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FIGURE LEGENDS 650 
Figure 1. Genetic ablation of Plk1 in adult mice. (a) Survival curve of 3-month-old 651 
mice of the indicated genotypes: Plk1(+/Δ); Cre-ERT, Plk1(Δ/Δ); Cre-ERT, and 652 
Plk1(lox/lox) (in the absence of the Cre allele) injected with three doses of tamoxifen 653 
(arrows). Log-rank Test (Mantel-Cox) ***, p<0.001. (b) Body weight of the mice 654 
shown in a (mean ± SD) . One-Way Anova; ***, p<0.001. (c) H&E staining of the 655 
intestinal mucosa in 10-week-old Plk1(Δ/Δ) and Plk1(lox/lox) control mice. The 656 
architecture is disrupted in Plk1(Δ/Δ) mice, where abnormal mitotic figures are 657 
observed (monopolar-like structures; arrows in the inset). Scale bars, 200 μm. Images 658 
are representative of 3 Plk1(lox/lox) and 8 Plk1(Δ/Δ) mice analyzed. (d) Left, 659 
immunohistochemical detection of phospho-Ser10 Histone H3 (pH3) and Plk1 in 660 
Plk1(lox/lox) (top row) and Plk1(Δ/Δ) (bottom row) mice. Scale bars, 50 μm. Top right, 661 
quantification of the percentage of pH3- and Plk1-positive cells (Columns indicate 662 
mean; n>500 cells from 3 mice per genotype). ***, p<0.001; 2-way ANOVA test. 663 
Bottom right, high magnification image of an aberrant mitotic (positive for pH3) cell 664 
that is negative for Plk1 staining. The dashed yellow line depicts the cell contour, and 665 
arrow heads indicate the spindle poles. Scale bar, 10 μm. (e) Survival curve of Plk1(+/–666 
) mice [red; n=21; 11 females (blue) and 10 males (purple)] versus Plk1(+/+) controls 667 
(n=23) over 24 months.  **, p<0.01; Log-rank Test (Mantel-Cox). (f) Orcein staining to 668 
highlight elastic fibers and H&E staining of the aorta of a Plk1(+/–) mouse, showing 669 
aortic rupture (open arrowhead, left micrograph) accompanied by fragmentation of 670 
elastic fibers (closed arrowheads, middle micrograph) and intramural hematoma 671 
(arrowheads, right micrograph). Scale bars, 200 μm (left) and 50 μm (middle and right). 672 
(g) Left, Van Gieson staining for elastin in aortic walls of 20-week-old Plk1(+/+) and 673 
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Plk1(+/–) mice. Scale bars, 50 μm. Right, quantification of the number of elastic fiber 674 
breaks per section (mean ± SD; n=3 sections from 4 [Plk1(+/–) AS and Plk1(+/+) DIA] 675 
or 5 (all other groups) mice. AS, ascending aorta; DIA, diaphragmatic abdominal aorta; 676 
SR, suprarenal abdominal aorta. (h) Left, representative ultrasound images of the aorta 677 
in 20-week-old Plk1(+/+) and Plk1(+/–) mice. Yellow dashed arrows indicate the aortic 678 
internal diameter. Scale bars, 1 mm. Right, quantification of the maximal aortic 679 
diameter (mean ± SD; n=7 wild-type and 5 heterozygous mice per group) of the 680 
indicated regions of the aorta. In (g, h), **, p<0.01; ***, p<0.001; Student’s t-test. 681 
 682 
Figure 2. Plk1 function in VSMCs in vivo (a) Representative analysis of Plk1 alleles by 683 
PCR amplification. The presence of the lox and Δ alleles was determined in the aorta 684 
(A) and heart (H) of 10-week-old Plk1(lox/lox);SM22-Cre mice without tamoxifen 685 
(TAM) treatment [Plk1(lox/lox) genotype] or with TAM treatment [Plk1(Δ/Δ)SM 686 
genotype[. (b) Plk1 mRNA levels (relative to Gapdh mRNA levels) in the indicated 687 
tissues from Plk1(lox/lox) and Plk1(Δ/Δ)SM mice. Columns indicate mean; n=3 mice per 688 
group; *, p<0.05; ns, not significant; Student’s t-test. (c) Internal diameter of the 689 
ascending (AS), diaphragmatic (DIA) and suprarenal (SR) aorta scored by ultrasound 690 
measurements in 20-week-old Plk1(lox/lox) (n=9) and Plk1(Δ/Δ)SM (n=10) mice. *, 691 
p<0.05; Student t-test analysis. (d) Systolic blood pressure of Plk1(Δ/Δ)SM and 692 
Plk1(lox/lox) mice, as measured by a tail-cuff system (horizontal bars indicate mean). 693 
***, p<0.001; Student t-test. (e) Analysis of the elasticity of aortic rings from 694 
Plk1(Δ/Δ)SM or Plk1(lox/lox) mice using a myograph (mean ± SEM). *, p<0.05; **, 695 
p<0.01; ***, p<0.001; Two-Way Anova analysis. (f) Contraction force in aortic rings 696 
from mice with the indicated genotypes in the presence of the indicated concentrations 697 
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of angiotensin II (Ang II) and phenylephrine (PE). Contraction is expressed as a 698 
percentage of the maximal KCl-induced contraction. Data are mean ± S.D.. (***, 699 
p<0.0001; Extra sum-of-squares F test). (g) Systolic blood pressure of Plk1(Δ/Δ)SM and 700 
Plk1(lox/lox) mice infused with AngII for the indicated amounts of time. The curves 701 
drawn represent the One-phase association nonlinear fit approximation (mean ± SEM; 702 
n=7 Plk1(lox/lox) and n=8 Plk1(Δ/Δ)SM mice). *, p<0.05; Student’s t-test #, p<0.05; ##, 703 
p<0.01; Two-Way Anova analysis. (h) Heart weight normalized to tibia length in mice 704 
from panel g treated with AngII [Plk1(lox/lox) n=7; Plk1(Δ/Δ)SM n=8] or untreated 705 
[Ctrl; Plk1(lox/lox) n=18; Plk1(Δ/Δ)SM n=7] at the end of the experiment**, p<0.01; 706 
***, p<0.001 Student’s t-test. (i) Left ventricle (LV) septum and posterior wall 707 
thickness, as assessed by ultrasound, in mice from panel g treated with AngII 708 
[Plk1(lox/lox) n=7; Plk1(Δ/Δ)SM n=8] or untreated [Ctrl; Plk1(lox/lox) n=9; 709 
Plk1(Δ/Δ)SM n=10] at the end of the experiment. *, p<0.05; Student’s t-test. (j) 710 
Quantification of cardiomyocyte area in mice from panel g treated with AngII or 711 
untreated (Ctrl) at the end of the experiment. The area of >500 cardiomyocytes per 712 
mouse (individual columns) were measured by staining with fluorescein isothiocyanate-713 
conjugated wheat lectin. ***, p<0.001; One-way Anova. (k) Van Gieson staining of 714 
elastin (left; arrowheads indicate fiber breaks) and quantification of these breaks (right) 715 
in the wall of the ascending aorta of mice from panel g treated with AngII 716 
[Plk1(lox/lox) n=7; Plk1(Δ/Δ)SM n=7] or untreated [Ctrl; Plk1(lox/lox) n=6; 717 
Plk1(Δ/Δ)SM n=7] at the end of the experiment  *, p<0.05; **, p<0.01; One-way Anova 718 




Figure 3. Plk1 modulates the RhoA pathway in interphase VSMCs. (a) Schematic 721 
representation of the cellular protocol used for the analysis of interphase VSMCs. (b) F-722 
actin staining to visualize cell morphology and actin stress fibers in Plk1(lox/lox) and 723 
Plk1(Δ/Δ) VSMCs 6 h after seeding in the presence of LPA (2 µM) as depicted by. 724 
Scale bars, 20 μm. (c) Cell roundness factor of Plk1(lox/lox) and Plk1(Δ/Δ) VSMCs that 725 
were plated in the presence or absence of 2 μM LPA and incubated for 2 or 6 hours 726 
after plating. Each circle represents a single cell and bars indicate the mean (n>50 cells 727 
per group in 3 different experiments). *, p<0.05; ***, p<0.001; One-Way Anova. (d) 728 
Top, immunoblotting for Plk1, phosphorylated Mypt1 (pMypt1 Thr696) and MLC 729 
(pMLC Ser18/19) after treatment of VSMCs of the indicated genotypes with 0.5 μM 730 
AngII for 5 min in Total Mypt1, MLC and α-tubulin were used as loading controls. 731 
Images are representative of three independent experiments. Bottom, representative 732 
images of the actin cytoskeleton (green) and MLC phosphorylation (red) in AngII-733 
treated cells are shown. DAPI (blue) was used to stain the DNA. Scale bars, 20 μm. (e) 734 
Immunoblotting for active and total RhoA in pull-downs using the rhotekin-binding 735 
domain (RBD) as a bait from lysates of VSMCs of the indicated genotypes without or 736 
with LPA treatment for 5 min. A representative blot is shown from 3 different 737 
experiments. (f) Immunoblotting for active and total RhoA activity (RBD pull-downs) 738 
and pMLC after treatment of wild-type VSMCs without or with AngII and the indicated 739 
Plk1 inhibitors (GW, GW843682X; BI, BI2536). Total RhoA and α-tubulin were used 740 
as loading controls. (g) Cell roundness factor of wild-type VSMCs plated in the 741 
presence of 2 μM BI2536 (+) or DMSO (–). The cells were plated in the presence of 2 742 
μM LPA and the cell roundness factor was measured 2 and 10 h after plating. Bars 743 
indicate mean (n>50 cells per group in 3 different experiments). **, p<0.01; One-Way 744 
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Anova. (h) Contraction force test in aortic rings isolated from 6-8-month old mice in 745 
untreated (Control) or treated with DMSO or BI2536. The rings were stimulated with 746 
increasing concentrations of angiotensin II (AngII; Control n=8; DMSO n=4; BI2536 747 
n=4 mice) or phenylephrine (PE; Control n=6; DMSO n=6; BI2536 n=5 mice). 748 
Contraction is expressed as a percentage of the maximal induced contraction reached in 749 
the untreated samples. Data are mean ± S.D. (p<0.0001; Extra sum-of-squares F test). 750 
(i) Representative images of phalloidin staining to visualize VSMC morphology and F-751 
actin staining in Plk1(lox/lox) VSMCs (top row) and Plk1(Δ/Δ) VSMCs (middle row) 752 
transfected with either a control retrovirus (empty vector, EV) or a retrovirus expressing 753 
the constitutively active RhoA-Q63L mutant. In addition, Plk1(lox/lox) cells that had 754 
been transfected with EV or the RhoA-Q63L mutant were treated with the ROCK 755 
inhibitor Y27632 (1 μM) (bottom row). Scale bars, 20 μm. (j) Cell roundness factor of 756 
VSMCs from i 10 h after seeding. Bars indicate mean (n>50 cells per group in 3 757 
different experiments). *, p<0.05; **, p<0.01, ***, p<0.001; One-Way Anova test. 758 
Micrographs in (b,d,i) show representative images from 3 independent experiments. 759 
 760 
Figure 4. Plk1 modulates activation of the RhoA pathway by Ect2. (a) Transcriptional 761 
profiling of Ect2-, MyoGEF-, LARG-, p115GEF-, and RacGAP1-encoding transcripts 762 
in aortas of wild-type mice treated with AngII for the indicated number of days. 763 
Columns indicate mean; n=3 independent experiments; n.s., not significant; ***, 764 
p<0.001; 2-Way ANOVA. (b) Cell roundness factor of VSMCs 2 and 10 h after plating 765 
cells in the presence of 2 μM of LPA; the cells had been treated with scramble siRNAs 766 
(Scr), or siRNAs targeting transcripts encoding Ect2, MyoGEF, LARG, p155GEF, or 767 
RacGAP1. (c) Representative images of LPA-treated VSMCs transduced with Scr or 768 
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Ect2 or siRNA, 10 h after plating. Scale bars, 20 μm. (d) Cell roundness factor of wild-769 
type VSMCs after treatment with AngII and the indicated siRNAs, or after treatment of 770 
Plk1(Δ/Δ) VSMCs with AngII for 10 h. (sh1 and sh2 correspond to two different 771 
shRNAs against Ect2) In b and d, bars indicate mean (n>50 cells per group in 3 772 
different experiments). *, p<0.05; **, p<0.01; One-way ANOVA. (e) Immunoblotting 773 
for pMLC Ser19 in VSMCs treated as in d. The numbers indicate the relative level of 774 
phosphorylation in the presence of AngII versus scramble shRNA in the presence of 775 
AngII. α-tubulin was used as a loading control. (f) Left, immunoblotting for phospho-776 
RacGAP1 (Ser170) (top arrow) and phospho-MLC (Ser19) (bottom arrow) in serum-777 
starved VSMCs treated with 2 μM BI2536 or DMSO (Ctrl) and then stimulated with 2 778 
μM LPA for 10 or 30 min. Total MLC and α-tubulin were used as loading controls. 779 
Right, quantification of the phospho-RacGAP1 and phospho-MLC levels, normalized to 780 
α-tubulin or total MLC, respectively in three independent experiments (columns 781 
indicate mean). (g) Immunoblotting for phospho-RacGAP1 (Ser170) (top arrow), 782 
phospho-MLC (Ser19) (bottom arrow) in serum-starved VSMCs treated with BI2536 or 783 
DMSO (Ctrl) and then stimulated with either 2 μM AngII (A) or 2 μM LPA (L) for 30 784 
minutes. Total MLC was used as a loading control. Crtl samples were re-arranged from 785 
the same blot to correspond with BI2536-treated samples. (h) Immunoblotting for Ect2, 786 
wild-type GFP-RacGAP1 (RacGAP1WT) or a mutant form of RacGAP1 with four 787 
phospho-mimetic mutations in the Plk1 phospho-sites (RacGAP14D) in pull down 788 
experiments using GST-RhoA-G17A in extracts from HEK293 cells  expressing GFP-789 
Ect2, GFP-RacGAP1WT or GFP-RacGAP14D, respectively. Cells were stimulated with 2 790 
μM LPA for 20 min in the presence or absence of the Plk1 inhibitor BI2536. Data in 791 




Figure 5. Dynamic re-localization of Plk1 and Ect2 and its control by aPKC. (a) 794 
Immunofluorescent detection of endogenous Plk1 and phospho-MLC (pMLC) in 795 
untreated (NT, top) and AngII-treated (bottom) VSMCs, showing re-localization of 796 
Plk1 to the membrane edge upon AngII treatment, where Plk1 (red) co-localizes with 797 
phospho-MLC(Ser18/19) (green). Insets show single-channel images of the boxed 798 
regions. Actin fibers are visualized using phalloidin coupled to Alexa647 dye. DNA is 799 
counterstained with DAPI (blue). Scale bars, 10 μM (b) Time lapse images showing the 800 
localization of GFP-Ect2 to the cell edge and membrane protrusions (arrowheads) at the 801 
indicated time points after LPA treatment. Insets show higher magnification views of 802 
the boxed regions. The corresponding phase contrast images are also shown.  Scale bar, 803 
10 μM. (c) Immunoblotting for GFP-Ect2 or myc-Plk1 in HEK293 cells expressing 804 
GFP-Ect2 and myc-Plk1. The cells were treated with 2 μM LPA for the indicated time 805 
points with or without 1 μM PKC inhibitor Go6983. Top, cell lysates were subjected to 806 
myc-Plk1 immunoprecipitation (myc IP), and the immunoprecipitates were probed with 807 
anti-GFP or anti-myc antibodies. Numbers indicate the quantification of GFP-Ect2 band 808 
intensity in the IP versus input. Bottom, GFP-Ect2 and myc-Plk1 in the total cell extract 809 
(input). (d) Cell roundness factor of Plk1-null VSMCs (Δ/Δ) and wild-type cells 810 
(lox/lox) that were untreated or treated with either the ROCK inhibitor Y27632 (1 μM) 811 
or the PKC inhibitor Go6983 (1 μΜ). Mean ± SEM; n>50 cells per group in 3 different 812 
experiments. *, p<0.05; One-way ANOVA. (e) Top, immunoblotting for GFP-Ect2 and 813 
RhoA-G17A in pull-down experiments performed with GST-RhoA-G17A beads, using 814 
extracts from HEK293 cells, treated without or with LPA, expressing GFP-Ect2-WT, 815 
GFP-Ect2-T327A or GFP-Ect2-14A.RhoA-G17A was used as a control to show equal 816 
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loading of the coated beads. Numbers indicate the quantification of GFP-Ect2 band 817 
intensity in the IP versus input. Bottom, GFP-Ect2 in the total cell extracts (input). 818 
Lanes 1-4 and 5-6 were splitetd from the same blot membrane. (f) Top, immunoblotting 819 
for GFP-Ect2 in pull-down experiments performed with beads coated with GST-Plk1-820 
PBD, using extracts of LPA-stimulated HEK293 cells expressing either wild-type (WT) 821 
GFP-Ect2 or the GFP-Ect2-T327A mutant. Numbers indicate the quantification of GFP-822 
Ect2 band intensity in the IP versus input. Red Ponceau staining was used to monitor 823 
protein loading. Bottom, GFP-Ect2 in the total cell extracts (input). (g) Cell roundness 824 
factor of VSMCs treated with scramble shRNA (Scr) or two different shRNAs targeting 825 
mouse Ect2 (sh1 and sh2). The cells were untransfected or expressed human wild-type 826 
Ect2 (WT) or the Ect2-T327A mutant. Data in (c,e,f) show representative blots from 2 827 
independent experiments.  828 
 829 
Figure 6. Plk1 inhibition impairs vascular homeostasis in vivo. (a) Experimental design. 830 
Twelve-week-old mice were injected twice per week with volasertib (15 mg/kg; n=13) 831 
or DMSO (n=11) for three weeks (red arrows). One week later, 8 mice from the 832 
volasertib group and 6 mice from the DMSO control group were treated with AngII 833 
(blue arrow) (b) Elasticity of aortic rings, as assessed using a myograph, from mice 834 
treated with DMSO (n=4 rings per mouse; 4 mice) or volasertib (n=4 rings per mouse; 4 835 
mice) for two months. ***, p<0.001; Two-way Anova analysis. (c) Normalized blood 836 
pressure in DMSO treated mice (Ctrl), AngII, volasertib or the combination of AngII 837 
plus volasertib . Time 0 was immediately before AngII pump implantation. *, p<0.05; 838 
**, p<0.01; ***, p<0.001; Two Way-Anova. Red asterisks denote statistical 839 
significance between control+AngII treated mice and volasertib+AngII mice. Blue 840 
asterisks indicate statistical significance between control+AngII treated mice and non-841 
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AngII treated animals. (d) Heart weight of mice from c, normalized to tibia length. 842 
DMSO-Control n=4; DMSO-AngII n=6; Volasertib-Control n=5; Volasertib-AngII n=6 843 
mice; **, p<0.01; Student t-test. (e) Internal diameter of ascending (AS), diaphragmatic 844 
(DIA) and suprarenal (SR) aorta, as assessed by ultrasound, in 20-week-old mice from 845 
panel c. DMSO-Control n=5; DMSO-AngII n=6; Volasertib-Control n=5; Volasertib-846 
AngII n=8 mice;  *, p<0.05; **, p<0.01; Student t-test analysis. (f) Van Gieson staining 847 
for elastin. Left, quantification of elastic breaks in the ascending [DMSO-Control n=5; 848 
DMSO-AngII n=6; Volasertib-Control n=4; Volasertib-AngII n=8 mice] and abdominal 849 
[DMSO-Control n=5; DMSO-AngII n=6; Volasertib-Control n=5; Volasertib-AngII 850 
n=8 mice] aortic walls from mice in panel c. Right, representative images of the 851 
abdominal aorta from the groups of mice indicated in panel a. *, p<0.05; **, p<0.01; 852 
***, p<0.001. Student t-test analysis. Scale bars, 100 μm. (g) Representative 853 
macroscopic (top) and microscopic images of the abdominal aorta of 20-week-old mice 854 
treated with AngII and DMSO or volasertib, showing the presence of aortic aneurysm 855 
and aortic wall rupture in AngII plus volasertib treated mice. Hematoxylin and Eosin 856 
(H&E) staining (second and third rows) and elastin Van Gieson staining (EVG, bottom 857 
row) are shown. Arrowheads indicate rupture of the aorta wall. Histology images are 858 
representative of the three aortas per group in the upper panel. Scale bars, 0.5 mm (top 859 





ON-LINE METHODS  863 
Mice. The Plk1(lox) and Plk1(–) alleles were recently described13,14. For whole-body 864 
conditional ablation of Plk1, we used the RERT2 allele, which carries a tamoxifen-865 
inducible Cre recombinase ubiquitously expressed under the regulatory sequences of 866 
RNA polymerase II15. Mice (Mus musculus) were maintained in a mixed 129/Sv x 867 
C57BL/6J background and both males and females were indistinctly used unless 868 
otherwise specified. Wild-type female mice in the volasertib experiments were pure 869 
C57BL/6J background. Plk1(+/lox) and Plk1(lox/lox) mice were used to generate 870 
Plk1(+/Δ) and Plk1(Δ/Δ) mice, respectively, after i.p. injection with tamoxifen citrate 871 
salt (0.1 mg/g of animal weight). Quantitative analysis of blood cell populations was 872 
performed in 10-20-week-old mice using a veterinary hematology analyzer Procount 873 
(Ser nr. 901235) using K3-EDTA 3K (Aquisel #1501126) as an anticoagulant. For 874 
specific ablation of Plk1 in VSMCs, we used the SM22-Cre model reported 875 
previously17. 10-week-old mice were fed ad libitum with a tamoxifen-supplemented diet 876 
(Harlan Laboratories Models) and analyzed after 8-12 weeks of treatment. For AngII 877 
perfusion, subcutaneous micro-osmotic pumps (Alzet) were used. AngII (Sigma) was 878 
diluted in saline buffer and loaded into these osmotic pumps to obtain a delivery ratio of 879 
0.5 μg/kg/min over the course of two (Alzet 1002) or four weeks (Alzet 1004).  For 880 
volasertib treatment, 3-month-old mice were intravenously injected with either 15 881 
mg/kg BI6727 (Selleckchem) as reported previously61 or with 1% DMSO in saline 882 
buffer as a control, twice per week following the scheme represented in Fig. S6a. 883 
GW843682X (Selleckchem) was injected at 8.5 mg/kg intraperitoneally every 4 days 884 
for 2 weeks. Sample sizes were estimated based on previously published experiments 885 
and mice were not randomized. The investigators were not blinded to experimental 886 
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group in outcome assessment. Mice were housed at the pathogen-free animal facility of 887 
the Centro Nacional de Investigaciones Oncológicas (CNIO, Madrid) following the 888 
animal care standards of the institution. These animals were observed on a daily basis 889 
from birth to death and sick mice were euthanized humanely in accordance with the 890 
Guidelines for Humane End Points for Animals used in biomedical research.  891 
 892 
Anatomical, cytological and histological analysis. Heart weight was measured after 893 
heart dissection and cleaning of the surrounding fat tissue. Heart weight (mg) was then 894 
normalized versus the tibia length (mm) for each animal. Heart left ventricle septum and 895 
posterior wall thickness were measured either in post-mortem histological heart 896 
sections, or in vivo by echocardiography (Vevo 2100 ecography device, VisualSonics, 897 
Toronto). For histological observation, dissected organs were fixed in 10%-buffered 898 
formalin (Sigma) and embedded in paraffin wax. Three- or five-micrometer-thick 899 
sections were stained with hematoxylin and eosin (H&E), Orcein, or Elastin Van 900 
Gieson’s (EVG) for elastic fiber detection, fluorescein isothiocyanate-conjugated wheat 901 
lectin (FITC-WGA) for measuring cardiomyocyte size, and Alcian Blue to detect 902 
mucopolysacharide deposition. Elastic fiber breaks were quantified using at least three 903 
different sections of the same aortic region in all treated animals. Similarly, 904 
cardiomyocyte area was quantified from three different heart sections in each sample 905 
from all treated animals. Additional immunohistochemical examination of tissue was 906 
performed using specific antibodies against Ki67 (Master Diagnostica), phospho-907 
histone H3 Ser10 (Millipore 06-570), or a new monoclonal antibody generated against 908 
human Plk113,14. 909 
For transmission electron microscopy, aortas were dissected and sliced into 910 
small fragments of 3 mm to 5 mm each. Aorta slices were then fixed in a mixture of 911 
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1.25% glutaraldehyde + 2.5% paraformaldehyde in PBS for 2 hours, and subsequently 912 
in a 2% osmium tetroxide solution. Fixed aortas were then embedded in Lowicryl 913 
plastic resin (Polyscience, Warrington – PA) following the manufacturer’s instructions. 914 
Ultrathin cuts of 60 nm were mounted in formvar coated nickel grids and examined 915 
using a JEOL JEM-100CX transmission electron microscope at 60kV voltage. 916 
 917 
Arterial contractility and elasticity. Thoracic aortas or mesenteric arteries were 918 
removed from 30-week-old mice, and placed in chilled Krebs solution containing 118 919 
mM NaCl; 4.7 mM KCl; 2.5 mM CaCl2; 1.2 mM KH2PO4; 1.2 mM MgSO4; 25 mM 920 
NaHCO3; and 11 mM glucose. The pH of the solution after saturation with carbogen 921 
(95% O2 and 5% CO2 mixture) was 7.4. The aorta and first or second branch mesenteric 922 
arteries were carefully cleaned of fat and connective tissue and cut into rings (2 mm in 923 
length). Aortic rings were mounted between two steel wires (40 μm diameter) 924 
introduced through the lumen, onto a four channel wire myograph (DMT A/S, 925 
Denmark). Similarly mesenteric arteries were mounted between two tungsten wires (25 926 
μm). After an equilibration period of 20 minutes, all rings were normalized to a pressure 927 
equal to 90 mmHg. Aortic rings were set at a resting tension of 5 mN and allowed to 928 
equilibrate for 30 min. At the end of the equilibration period, the vessels were tested for 929 
responsiveness a hyperpotassium solution (KPSS, KCl 120 mM) and washed with 930 
Krebs solution. After that, cumulative concentration-response curves to phenylephrine 931 
(10-9-10-4 M) or angiotensin II (10-10-10-6 M) were performed in separate rings until the 932 
maximal response was consistent. Vasoconstrictor responses were expressed as a 933 
percentage of KCl-induced contractions. In some rings, after a period of washing and 934 
stabilization new concentration-response curves were repeated after 30-min incubation 935 
with either DMSO as solvent, BI2536, GO6983 or Y27632. Data were expressed as a 936 
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percentage of the maximal response to the agonist in the absence of the antagonist. In 937 
another series of experiments, aortic rings elasticity was tested 15 minutes after 938 
normalization process, by forcing the aortic rings to a progressive stretching from the 939 
basal level to a 150 μm distance, in steps of 10 μm every 50 sec, and measuring the 940 
tension reached in each step. The cumulative concentration-response curves, with and 941 
without the antagonists, were fitted to a logistic equation and analyzed using GradPad 942 
Prism 5.0 software. Each point indicates the mean ± standard error of the mean 943 
(S.E.M.). To compare concentration–response curves, statistical analysis was performed 944 
using the extra sum-of-squares F test principle.  945 
 946 
Blood pressure measurements and in vivo imaging. Mice arterial blood pressure was 947 
measured with an automated tail-cuff BP-2000 Blood Pressure Analysis System 948 
(Visitech Systems, Apex, NC, USA). In brief, mice were trained for BP measurements 949 
conditions for one week on a daily basis. After training, the BP was measured twice 950 
before implantation of angiotensin II (AngII) pumps, to determine the basal blood 951 
pressure values in each mice cohort. Blood pressure measurements were performed by 952 
placing mice in tail-cuff restrainers over a warmed surface (39 ºC). Fifteen consecutive 953 
systolic blood pressure measurements were done, and the last ten readings per mouse 954 
were recorded and averaged. 955 
Ascending and descending aortic diameter was monitored in isofluorane-956 
anaesthetized mice by the high-frequency ultrasound Vevo 2100 echography device 957 
(VisualSonics, Toronto). Images were taken at three levels of the aorta: ascending (AS), 958 
diaphragmatic abdominal (DIA) and suprarenal abdominal (SR) aorta. Maximal internal 959 




RNA analysis. For microarray expression analysis, total RNA was extracted from 962 
aortas of mice at the age of 3-5 months, using Trizol reagent as indicated in 963 
manufacturer´s instructions (Invitrogen). The quality of obtained RNA was evaluated 964 
using the Lab-Chip technique (Agilent Bioanalyzer). Samples were then fluorescently 965 
labeled by in vitro transcription following the Two-Color Microarray-Based Gene 966 
Expression Analysis protocol (Quick Amp Labeling Kit, Two-Color; Agilent p/n 5190-967 
0444). We used the Whole Mouse Genome Oligo Microarray (Agilent) containing 968 
44,000 probes (60mers) that correspond to 41,000 different transcripts, as verified and 969 
optimized by the manufacturer. The images were acquired and quantified by means of a 970 
confocal scanner and software (Agilent G2565BA and Feature Extraction). The 971 
expression levels were processed using standard methods of normalization, FDR (false 972 
discovery rate) determination, and pathway analysis (GeneSpring, Ingenuity Pathway 973 
Analysis). 974 
For single gene qRT-PCR analysis, RNA from mice aortas treated with AngII 975 
was extracted using Trizol and subsequently column-purified with the Absolutely RNA 976 
Miniprep Kit (Stratagene). Both cDNA synthesis and PCR amplification was performed 977 
using the SuperScript III One-Step RT-PCR System with Platinum® Taq DNA 978 
Polymerase (Invitrogen). Oligonucleotides used are listed in Supplementary Table 4. 979 
The amounts of mRNA were measured using SYBR Green, and amplification of the 980 
housekeeping gene GAPDH was used as a normalization control. All amplicons were 981 
analyzed using BioRad iQ5 Optical System Software (version 2.0.148.60623; BioRad; 982 
170-9753SE01).  983 
 984 
Cell culture, infection and transfection. Cells were grown in DMEM supplemented 985 
with 10% FBS, 1% pen/strep, and 1% L-glutamine. VSMCs were obtained following 986 
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the protocol described in ref. 62. Briefly, the aorta was dissected out from its origin at 987 
the left ventricle to the iliac bifurcation and washed thoroughly in cold PBS. We 988 
removed adventitia from the aorta using angled forceps, as viewed using a dissecting 989 
microscope. Aortas were then sliced into ~1–2 mm pieces and these were incubated for 990 
20 to 60 minutes in collagenase media [DMEM + 1% pen/strep + 1% L-glutamine + 991 
0.04% w/v collagenase type II (C6885 Sigma)]. Collagenase was inactivated by adding 992 
1 volume of DMEM + 10% FBS and the tissue was cleaned by repeated centrifugation 993 
and suspension in regular DMEM + 10% FBS. Aorta slices were then placed into tissue 994 
culture plates containing DMEM + 10% FBS and incubated for 2 days at 37 ºC. Once 995 
VSMC started to proliferate and attach to the plate, cells were trypsinized and 996 
expanded. Finally, VSMC were immortalized using the T121 construct that encodes the 997 
first 121 amino acids of the SV40 large T antigen63. Plk1 depletion was achieved by 998 
infecting serum starved Plk1(lox/lox) VSMCs with AdenoCRE viral particles 999 
(Ad5CMVCre supplied by University of Iowa Viral Vector Core Facility; Ref. #VVC-1000 
U). for 48 to 60 h. Transfection of siRNAs was done using the NEON nucleofection 1001 
system (Invitrogen). Expression of wild-type and T327A human Ect2 cDNAs was 1002 
achieved by lentiviral particle infection. Depletion of murine Ect2 [Sigma Mission 1003 
shRNAs TRCN0000190489 (sh1) and TRCN0000336440 (sh2)], Racgap1 (Sigma 1004 
Mission shRNA TRCN0000322156) or Arhgef12 (encoding LARG; Sigma Mission 1005 
shRNA TRCN0000109960) was performed by expressing lentiviral particles carrying 1006 
shRNAs against the indicated transcripts. We also used commercial siRNAs 1007 
(Dharmacon On-target pools) targeting Ect2 (LQ-047092), Arhgef12 (LQ-041056-01), 1008 





Immunofluorescence and morphological analysis in cultured cells. Cell morphology 1012 
analysis was done on VSMCs infected with AdenoCre viral particles, and/or 1013 
nucleofected with the indicated siRNAs or shRNAs; treated with inhibitors of Plk1 (2 1014 
μM BI2536), aPKC (1 μM Go6983) or ROCK (1 μM Y27632); or transduced with a 1015 
retroviral construct encoding the RhoA-Q63L constitutive active mutant64 or lentiviral 1016 
vectors expressing different human Ect2 cDNAs (Ref. 39). Cells were then trypsinized 1017 
and kept in suspension for 1 to 2 h in media without serum, to completely inhibit the 1018 
RhoA pathway65. Cells were then plated on gelatin coated coverslips in the presence or 1019 
absence of 2 μM lysophosphatidic acid (LPA) or 0.5 μM AngII, fixed in 4% 1020 
formaldehyde in PBS for 15 minutes and permeabilized with 0.5% Triton X-100 and 1021 
0.1% SDS in PBS for 10 minutes. Cells were then stained with antibodies against 1022 
phospho-MLC (Ser19; Cell Signaling #3675; 1:1000), or Plk1 (rat monoclonal clone 1023 
POE125; 1:200; Ref. 14); phalloidin coupled to a fluorescent dye (Molecular Probes) for 1024 
actin detection; and DAPI for DNA counterstaining. Cell images were captured at low 1025 
magnification (10x objective) with a Leica DMI6000 fluorescent microscope. 1026 
Roundness data were obtained by applying the formula (4·Area)/(π·(major axis)2), using 1027 
the morphology analysis tools available in ImageJ software. Roundness numbers range 1028 
from 0 to 1, where 1 indicates a perfectly round cell, and data below 1 indicates 1029 
elongated or polygonal cells. Similar quantification of the roundness or elliptic 1030 
morphology of mesenchymal cells has been previously used to describe these 1031 
morphological changes and their dependence on RhoA activity66. 1032 
 1033 
Protein extraction and immunoblotting. Cells were washed twice with ice-cold TBS 1034 
(150 mM NaCl; 50 mM TRIS/HCl; pH 7.5) and lysed in RIPA lysis buffer (37 mM 1035 
NaCl, 0.5% NP-40, 0.1% SDS, 1% TX-100, 20 mM Tris-HCl pH 7.4, 2 mM EDTA, 1036 
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10% glycerol, supplemented with protease and phosphatase inhibitory cocktails 1037 
(SIGMA). After 30 min on ice, samples were vortexed (5 min at 4 oC) and cleared by 1038 
centrifugation. Proteins were separated on XT Criterion Bis-Tris acrylamide gels 1039 
(BioRad), transferred to nitrocellulose membranes (BioRad), and probed using the 1040 
following specific antibodies: anti-phospho-RacGAP1 (Ser170; Active Motive #39265-1041 
66; 1:500); anti-phospho-MLC (Ser18/Ser19; Cell Signaling #3674; 1:1000)); anti-1042 
MLC (Cell Signaling #3672; 1:2000); anti-Plk1 (clone PL6/PL2; ThermoFIsher #33-1043 
1700; 1:500), anti-phospho-Mypt1-Thr696 (Cell Signaling #5163; 1:100); anti-Mypt1 1044 
(Santa Cruz Biotechnologies #sc-25618; 1:500) and anti-α-Tubulin (SIGMA, clone 1045 
DM1A; #T9026; 1:10000). Signal detection was done using secondary antibodies 1046 
coupled to Alexa 680 dye (Invitrogen) and using the Odyssey Infrared Imaging System 1047 
(Li-Cor Biosciences).  1048 
 1049 
GST pull downs. GST-RBD (Addgene; #15247) or GST-RhoA-G17A (obtained from 1050 
Channing J. Der, University of North Carolina; Ref.  67)  recombinant beads were 1051 
prepared as described in Refs. 68,69. Pull downs were performed in HEK293 cell lysates 1052 
expressing different GEF cDNA constructs. HEK293 cells were transfected with 1053 
plasmids encoding GFP-ECT2 39, GFP-LARG 70, GFP-p115GEF 70, GFP-RacGAP1 26 1054 
and (3x)myc-Plk1 71. After cDNA expression for 24 h, cells were incubated in RPMI 1055 
media without serum for 4 to 5 h and then induced with 2 μM LPA (SIGMA) for the 1056 
indicated times. For Plk1 or PKC inhibition, 2 μM of BI2536 (JS Research Chemicals 1057 
Trading, Germany) or 1 μM of Go6983 (Calbiochem) was added 1 to 2 h before LPA 1058 
addition. Cells were then washed in cold TBS, and then cold-lysed either in RBD lysis 1059 
buffer (50 mM TRIC/HCl, pH7.2; 500 mM NaCl, 10 mM MgCl2; 1% TX100; 0.5% 1060 
42 
 
sodium deoxycholate; and 0.1% SDS) or RhoA-G17A lysis buffer (50 mM Tris-HCl, 1061 
pH7.4; 15 0mM NaCl; 5mM MgCl2; and 1% TX100) supplemented with 0.5 mM DTT, 1062 
protease inhibitor cockatil (Roche), and phosphatase inhibitor cocktail (Calbiochem). 1063 
Lysates were immediately frozen in dry ice and stored at -80 ºC. Pull downs were done 1064 
by adding either GST-RBD or GST-RhoA-G17A beads to 0.5 mg of total protein cell 1065 
lysates. Beads were incubated in a rocking wheel at 4 ºC for 1 hour and then washed 1066 
three times in the appropriate lysis buffer. Finally, beads were drained in loading buffer 1067 
and proteins were separated on XT Criterion Bis-Tris acrylamide gels (BioRad), 1068 
transferred to nitrocellulose membranes (BioRad), and probed using the following 1069 
specific antibodies: anti-RhoA/B/C (Millipore clone 55, #05-778; 1:1000).; anti-GFP 1070 
(Roche, clones 7.1/13.1; #1 814 460; dilution 1:1000); anti-Plk1 (ThermoFIsher clone 1071 
PL6/PL2 #33-1700; 1:500) and anti-myc tag (Santa Cruz Biotechnologies, clone 9E10, 1072 
#sc-40; 1:1000).). 1073 
Plk1-PBD (residues 326-608) fused to GST (a generous gift from Michael 1074 
Yaffe; Ref. 25) was expressed in bacteria and coupled to glutathione-sepharose beads 1075 
(GE Healthcare). Plk1-PBD pull down assays were done similarly to the GST-RBD pull 1076 
down assays. 1077 
 1078 
Statistical analysis. Statistical analysis was performed using ANOVA analysis, two-1079 
sided Student’s t-test or Chi-square (Log-rank Mantel-Cox) tests or extra sum-of-1080 
squares F test principle. All data are shown as mean with standard deviation (SD) or 1081 
standard error of the mean (SEM). Probabilities of p < 0.05 were considered significant. 1082 
Detailed information on experimental design and reagents can be found in the Life 1083 
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 1113 
EDITORIAL SUMMARY  1114 
Although Plk1 has been studied primarily as a mitotic regulator in dividing cells, de 1115 
Cárcer et al. find that Plk1 deficiency or inhibition in mice leads to vascular defects, 1116 
including aortic aneurysm and rupture, as well as defective vascular smooth muscle 1117 
contractility. These results provide a note of caution to the clinical use of Plk1 inhibitors 1118 
as anti-cancer agents. 1119 
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